Correlation Between Zentalis Pharmaceuticals and Monopar Therapeutics

Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Monopar Therapeutics, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Monopar Therapeutics.

Diversification Opportunities for Zentalis Pharmaceuticals and Monopar Therapeutics

-0.05

Correlation Coefficient

Zentalis Pharmaceuticals  Monopar Therapeutics

Good diversification

The 3 months correlation between Zentalis and Monopar is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Monopar Therapeutics go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Monopar Therapeutics

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to under-perform the Monopar Therapeutics. In addition to that, Zentalis Pharmaceuticals is 1.17 times more volatile than Monopar Therapeutics. It trades about -0.07 of its total potential returns per unit of risk. Monopar Therapeutics is currently generating about 0.36 per unit of volatility. If you would invest  1,809  in Monopar Therapeutics on September 16, 2024 and sell it today you would earn a total of  729.00  from holding Monopar Therapeutics or generate 40.3% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Zentalis Pharmaceuticals Llc  vs.  Monopar Therapeutics

Zentalis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Monopar Therapeutics

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Zentalis Pharmaceuticals and Monopar Therapeutics

The main advantage of trading using opposite Zentalis Pharmaceuticals and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.

The idea behind Zentalis Pharmaceuticals Llc and Monopar Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.